Small-molecule factor D inhibitors targeting the alternative complement pathway

被引：0

作者：

Jürgen Maibaum

Sha-Mei Liao

Anna Vulpetti

Nils Ostermann

Stefan Randl

Simon Rüdisser

Edwige Lorthiois

Paul Erbel

Bernd Kinzel

Fabrice A Kolb

Samuel Barbieri

Julia Wagner

Corinne Durand

Kamal Fettis

Solene Dussauge

Nicola Hughes

Omar Delgado

Ulrich Hommel

Ty Gould

Aengus Mac Sweeney

Bernd Gerhartz

Frederic Cumin

Stefanie Flohr

Anna Schubart

Bruce Jaffee

Richard Harrison

Antonio Maria Risitano

Jörg Eder

Karen Anderson

机构：

[1] Novartis Institutes for BioMedical Research,Drug Discovery Department

[2] Novartis Pharma AG,Department of Clinical Medicine and Surgery, Division of Hematology

[3] Novartis Campus,undefined

[4] Novartis Institutes for BioMedical Research,undefined

[5] Evonik Japan Co.,undefined

[6] Shinjuku-ku,undefined

[7] Pharma Research and Early Development,undefined

[8] Roche Innovation Center Basel,undefined

[9] Actelion Pharmaceuticals Ltd.,undefined

[10] Institute of Infection and Immunity,undefined

[11] School of Medicine,undefined

[12] Cardiff University,undefined

[13] Henry Wellcome Building,undefined

[14] Heath Park,undefined

[15] University of Naples,undefined

来源：

Nature Chemical Biology | 2016年 / 12卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

A fragment-based design approach identifies reversible inhibitors targeting human protease complement factor D (FD), which is required for amplification of complement C3 signaling. FD inhibitors act as systemic regulators of complement activation in vivo.[graphic not available: see fulltext]

引用

页码：1105 / 1110

页数：5

共 50 条

[41] Structural characteristics of small-molecule inhibitors targeting FTO demethylase
Gao, Shuting
Li, Xitong
Zhang, Miao
Zhang, Ning
Wang, Ruiyong
Chang, Junbiao
FUTURE MEDICINAL CHEMISTRY, 2021, 13 (17) : 1475 - 1489
[42] Targeting Mycobacterium tuberculosis Topoisomerase I by Small-Molecule Inhibitors
Godbole, Adwait Anand
Ahmed, Wareed
Bhat, Rajeshwari Subray
Bradley, Erin K.
Ekins, Sean
Nagaraja, Valakunja
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (03) : 1554 - 1562
[43] The development of small-molecule inhibitors targeting HPK1
Zhou, Lixin
Wang, Tianyu
Zhang, Kuojun
Zhang, Xiangyu
Jiang, Sheng
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 244
[44] The development of small-molecule inhibitors targeting CD47
Yu, Wei-Bang
Ye, Zi-Han
Chen, Xiuping
Shi, Jia-Jie
Lu, Jin-Jian
DRUG DISCOVERY TODAY, 2021, 26 (02) : 561 - 568
[45] Discovery of selective FactorD inhibitors targeting the alternative complement pathway
Karki, Rajeshri
Powers, James
Belanger, David
Liu, Donglei
Ji, Nan
Jendza, Keith
Gelin, Christine
Flohr, Stefanie
Lorthiois, Edwidge
Vulpetti, Anna
Mac Sweeney, Aengus
Anderson, Karen
Mogi, Muneto
Mainolfi, Nello
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
[46] Targeting the miRNA pathway with small-molecule modulators of Argonaute protein
Quaranta, Roberto
Masciarelli, Silvia
Fazi, Francesco
Del Rio, Alberto
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
[47] Small-Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics
Peukert, Stefan
Miller-Moslin, Karen
CHEMMEDCHEM, 2010, 5 (04) : 500 - 512
[48] Activation of alternative complement pathway without complement factor D
Zhang, Yuzhou
Keenan, Adam
Lindorfer, Margaret A.
Pitcher, Gabriella R.
Taylor, Ronald P.
Lambris, John D.
Smith, Richard J. H.
MOLECULAR IMMUNOLOGY, 2017, 89 : 173 - 173
[49] Recent Advances in Wnt/β-Catenin Pathway Small-Molecule Inhibitors
Holsworth, Daniel D.
Krauss, Stefan
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 47, 2012, 47 : 393 - 409
[50] Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions
Jones, Dylan T.
Harris, Adrian L.
EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (05) : 463 - 480

← 1 2 3 4 5 →